Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?

Diabetic medicine : a journal of the British Diabetic Association - 1 Jul 2008

Karlsson E, Shaat N, Groop L

Abstract excerpt

AIMS: Genetic testing is needed for the formal diagnosis of maturity-onset diabetes of the young (MODY), but this is not widely available. If any MODY biomarkers were known, these could possibly be used as an alternative. Hepatocyte nuclear factor (HNF)-1alpha and HNF-4alpha regulate transcriptio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Case-Control Studies
Share to Complement C5

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Hepatocyte Nuclear Factor 1-alpha

Share to Hepatocyte Nuclear Factor 4

Share to Prealbumin

Share to Trans-Activators

Source

Identifiers

PMID: 18513302
DOI: 10.1111/j.1464-5491.2008.02467.x

Genes

TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18513302-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?PMID 18513302Read ↗

High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.Semantic proximity Read ↗

Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.Semantic proximity Read ↗

Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.Semantic proximity Read ↗

Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult–Onset Nonautoimmune DiabetesSemantic proximity Read ↗

Mutations in HNF1A result in marked alterations of plasma glycan profile.Semantic proximity Read ↗

A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.Semantic proximity Read ↗

Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes.Semantic proximity Read ↗

Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young.Semantic proximity Read ↗

Maturity onset diabetes of the young and fibrin-related thrombosis risk.Semantic proximity Read ↗

The genetic abnormality in the beta cell determines the response to an oral glucose load.Semantic proximity Read ↗

Fucosylated AGP glycopeptides as biomarkers of HNF1A-Maturity onset diabetes of the young.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.